Neuland Laboratories Limited vs Jubilant Pharmova Limited
An objective side-by-side of NEULANDLAB and JUBLPHARMA, both in Pharmaceuticals - Indian - Bulk Drugs: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.
Prices as of 2026-09-21 close
Latest results: NEULANDLAB Mar 2026 · JUBLPHARMA Jun 2026
At a glance
- Neuland Laboratories Limited is the larger company by market value, about 1.7 times the size of Jubilant Pharmova Limited.
- On trailing earnings, Jubilant Pharmova Limited trades at the lower P/E (47.3 against 79.7).
- Neuland Laboratories Limited earns the higher return on equity (19.4% against 5.0%).
- Over three years Jubilant Pharmova Limited has grown profits faster (47% a year against 30%).
- Over the past year the share prices returned +44.3% (NEULANDLAB) and -6.5% (JUBLPHARMA).
| Metric | Neuland Laboratories NEULANDLAB |
Jubilant Pharmova JUBLPHARMA |
|---|---|---|
| Size and price | ||
| Market cap | ₹29,008 Cr | ₹16,619 Cr |
| Share price | ₹22,610 | ₹1,049 |
| Valuation | ||
| P/E | 79.66 | 47.29 |
| P/B | 15.47 | 2.34 |
| EV/EBITDA | 51.07 | 16.63 |
| PEG | 2.66 | 1.01 |
| Dividend yield | 0.2% | 0.5% |
| Profitability | ||
| ROE | 19.4% | 5.0% |
| ROCE | 27.0% | 9.0% |
| Operating margin | 28.4% | 14.1% |
| Sales (TTM) | ₹2,023 Cr | ₹8,607 Cr |
| Net profit (TTM) | ₹364 Cr | ₹351 Cr |
| Growth | ||
| Latest quarter sales YoY | +136.3% | +1385.3% |
| Latest quarter profit YoY | +666.0% | +3217.6% |
| Sales CAGR 3Y | +19.0% | +10.0% |
| Profit CAGR 3Y | +30.0% | +47.0% |
| Sales CAGR 5Y | +17.0% | +6.0% |
| Profit CAGR 5Y | +39.0% | -13.0% |
| Financial strength | ||
| Debt/Equity | 0.16 | 0.51 |
| Interest cover | 20.31 | 2.51 |
| Ownership | ||
| Promoter holding | 32.6% | 47.7% |
| Promoter change (4 qtrs) | -0.05 pp | +0.01 pp |
| Price performance | ||
| Return 1M | -4.06% | +20.46% |
| Return 3M | +31.27% | +9.70% |
| Return 1Y | +44.27% | -6.48% |
| Return YTD | +49.00% | -2.24% |
| Technical condition | ||
| Technical score | 48 | 84 |
| RS rating (1-99) | 90.00 | 62.00 |
| % vs 200-DMA | +34.84% | +9.45% |
| RSI (14) | 49.70 | 69.64 |
| % from 52-week high | -6.67% | -11.44% |
